Unique ID issued by UMIN | UMIN000022842 |
---|---|
Receipt number | R000026326 |
Scientific Title | Confirmation trial for body fat-reducing effect of a beverage containing the lactic acid bacterial strain CP1563 - A randomized, double-blind, placebo-controlled parallel group trial - |
Date of disclosure of the study information | 2016/06/24 |
Last modified on | 2017/12/25 10:55:49 |
Confirmation trial for body fat-reducing effect of a beverage containing the lactic acid bacterial strain CP1563 - A randomized, double-blind, placebo-controlled parallel group trial -
Trial for body fat-reducing effect of CP1563
Confirmation trial for body fat-reducing effect of a beverage containing the lactic acid bacterial strain CP1563 - A randomized, double-blind, placebo-controlled parallel group trial -
Trial for body fat-reducing effect of CP1563
Japan |
Healthy adults with BMI values over 23 but less than 30
Not applicable |
Others
NO
Effects of a lactic beverage containing CP1563 on the reduction of body fat, visceral fat and subcutaneous fat
Efficacy
Evaluate the effects of a beverage containing CP1563 on fat area determined by CT through the 18-week intervention period
Evaluate the effects of a beverage containing CP1563 on lipid and sugar metabolisms through the 18-week intervention period
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Placebo
2
Prevention
Food |
Daily intakes of a beverage containing CP1563 for 18 weeks
Daily intakes of a beverage without CP1563 for 18 weeks
20 | years-old | <= |
65 | years-old | > |
Male and Female
1. Subjects whose BMI values are over 23 but less than 30 (subjects of high normal and obesity class I)
2. Subjects whose visceral fat area is around 100 cm2
1. Persons who take drugs for adiposity, hypertension and dyslipidemia
2. Persons who cannot give up the intake of possible supplements which may affect the status of fat, blood pressure and plasma lipids
3. Persons who cannot terminate the consumption of foods containing large number of lactic acid bacteria during the trial
200
1st name | |
Middle name | |
Last name | Mamoru Oki |
Incorporated Medical Association Seishukai
Seishukai Clinic
3-18-5 Matsugatani, Taito-ku, Tokyo
03-3847-8866
mamoru.oki@seishukai.clinic.jp
1st name | |
Middle name | |
Last name | Yoshika Komori |
KSO Co., Ltd
Chairperson
1-9-7 Shibaura, Minato-ku, Tokyo
03-3452-7733
yoshi@kso.co.jp
Asahi Group Holdings, Ltd
Asahi Group Holdings, Ltd
Profit organization
NO
2016 | Year | 06 | Month | 24 | Day |
Unpublished
As results of having analyzed the data obtained in the trial using an analysis of covariance for repeated measures, significant differences in both total body fat and visceral fat areas between both groups were recognized.
Preinitiation
2016 | Year | 06 | Month | 23 | Day |
2016 | Year | 06 | Month | 25 | Day |
2017 | Year | 01 | Month | 29 | Day |
2017 | Year | 02 | Month | 17 | Day |
2017 | Year | 04 | Month | 10 | Day |
2017 | Year | 10 | Month | 31 | Day |
In the stratified analyses using an analysis of covariance for repeated measures, significant differences in both total body fat and visceral fat areas between both groups were also recognized.in subjects who have the initial visceral fat area less than 100cm2.
2016 | Year | 06 | Month | 22 | Day |
2017 | Year | 12 | Month | 25 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026326
Research Plan | |
---|---|
Registered date | File name |
2017/12/25 | CPS-008-01試験実施計画書20160620.doc |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |